Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GALR2 | O43603 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598786 | 1.00 | POLB (0.37) | POLBLMNAGALR2SMN1; SMN2PDE4A | |
| SCHEMBL28471596 | 0.85 | PDE4A (0.40) | LMNASMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL15655816 | 0.81 | GSK3B (0.48) | LMNAKDM4EHPGDMEN1KMT2A | |
| SCHEMBL17305955 | 0.80 | PDPK1 (0.40) | SMN1; SMN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15655815 | 0.78 | CDK2 (0.47) | POLBLMNAPDE4APDE4BPDE4C | |
| SCHEMBL3548733 | 0.77 | AXL (0.42) | PDPK1PARP1KDM4EMEN1KMT2A | |
| SCHEMBL9837779 | 0.77 | ALDH1A1 (0.45) | LMNAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3544906 | 0.77 | GPR35 (0.39) | POLBSMN1; SMN2PDPK1PARP1KDM4E | |
| SCHEMBL30488581 | 0.77 | AXL (0.42) | PDPK1PARP1KDM4EMEN1KMT2A | |
| SCHEMBL15668241 | 0.77 | MEN1 (0.38) | PDE4BMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4458830-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118201933-A | Tri-fused ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117263952-A | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-111836814-B | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023125121-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-111836814-A | Fused ring compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2019214546-A1 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2007044050-A2 | 1H-IMIDAZO[4,5-D]THIENO[3,2-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | POLB 1973/4885LMNA 1963/4885GALR2 3747/4885 |
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B1, CYP11B2, CYP2D6 | POLB 2591/4885LMNA 427/4885GALR2 1680/4885 |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | POLB 1973/4885LMNA 1963/4885GALR2 3747/4885 |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, IRAK4 | POLB 2988/4885LMNA 4653/4885GALR2 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.